ArticleJAC-antimicrobial resistance2020
Bacterial pneumonia coinfection and antimicrobial therapy duration in SARS-CoV-2 (COVID-19) infection.
Article in JAC-antimicrobial resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 50 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis.The Lancet. Microbe · 2023Pooled it
- Bacterial co-infection and antibiotic stewardship in patients with COVID-19: a systematic review and meta-analysis.BMC infectious diseases · 2023Pooled it
- Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis.PloS one · 2021Pooled it
- Factors influencing antibiotic use in confirmed viral respiratory tract infections.The Journal of antimicrobial chemotherapy · 2026Observational
- Factors Influencing Antimicrobial Choice and Duration During the Last Month of Life in Hospitalized Patients.Open forum infectious diseases · 2025Article
- Impact of COVID-19 pandemic on antimicrobial resistance of Proteus mirabilis in a Brazilian hospital.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- From Routine to Crisis: The Impact of COVID-19 Pandemic on Antibiotic Consumption in Iran.Health science reports · 2024Article
- How did the COVID-19 pandemic affect antibiotic consumption within humanitarian emergencies? Results from five humanitarian contexts.Infection prevention in practice · 2024Article
- Antimicrobial consumption in an acute NHS Trust during the COVID-19 pandemic: intervention time series analysis.JAC-antimicrobial resistance · 2024Article
- Healthcare commissioners' experience with antibiotic resistance during the COVID-19 pandemic in Saudi Arabia: a qualitative study.Journal of pharmaceutical policy and practice · 2024Article
- Predictors of developing severe COVID-19 among hospitalized patients: a retrospective study.Frontiers in medicine · 2024Article
- The Trend of Antibiotic Consumption After the COVID-19 Pandemic: Approach to Future Outbreaks.Infection and drug resistance · 2024Article
- Saliva microbiome in relation to SARS-CoV-2 infection in a prospective cohort of healthy US adults.EBioMedicine · 2023Article
- Cyclodextrins and Their Polymers Affect Human Serum Albumin's Interaction with Drugs Used in the Treatment of Pulmonary Infections.Pharmaceutics · 2023Article
- The Hidden Cost of COVID-19: Focus on Antimicrobial Resistance in Bloodstream Infections.Microorganisms · 2023Review
- The state of current research on COVID-19 and antibiotic use: global implications for antimicrobial resistance.Journal of health, population, and nutrition · 2023Article
- Survey of healthcare worker perceptions of changes in infection control and antimicrobial stewardship practices in India and South Africa during the COVID-19 pandemic.IJID regions · 2023Article
- Coinfection of SARS-CoV-2 with other respiratory pathogens in outpatients from Ecuador.Frontiers in public health · 2023Article
- Increasing Consumption of Antibiotics during the COVID-19 Pandemic: Implications for Patient Health and Emerging Anti-Microbial Resistance.Antibiotics (Basel, Switzerland) · 2022Review
- Antimicrobial use and aetiology of bloodstream infections in critically ill patients during early stages of SARS-CoV-2 pandemic.Infection prevention in practice · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundBacterial respiratory coinfection in the setting of SARS-CoV-2 infection remains poorly described. A description of coinfection and antimicrobial usage is needed to guide ongoing antimicrobial stewardship.
objectivesTo assess the rate of empirical antimicrobial treatment in COVID-19 cases, assess the rate and methods of microbiological sampling, assess the rate of bacterial respiratory coinfections and evaluate the factors associated with antimicrobial therapy in this cohort.
methodsInpatients with positive SARS-CoV-2 PCR were recruited. Antibiotic prescription, choice and duration were recorded. Taking of microbiological samples (sputum culture, blood culture, urinary antigens) and culture positivity rate was also recorded. Linear regression was performed to determine factors associated with prolonged antimicrobial administration.
resultsA total of 117 patients were recruited; 84 (72%) were prescribed antimicrobial therapy for lower respiratory tract infections. Respiratory pathogens were identified in seven (6%) patients. The median duration of antimicrobial therapy was 7 days. C-reactive protein level, oxygen requirement and positive cultures were associated with prolonged duration of therapy.
conclusionsThe rate of bacterial coinfection in SARS-CoV-2 is low. Despite this, prolonged courses of antimicrobial therapy were prescribed in our cohort. We recommend active antimicrobial stewardship in COVID-19 cases to ensure appropriate antimicrobial prescribing.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.